Zoetis investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Zoetis Inc. (“Zoetis”) (NYSE: ZTS) between February 16, 2021 and April 11, 2024.
On April 12, 2024, The Wall Street Journal published an article on Zoetis reporting that health regulators in the U.S. and Europe have received thousands of complaints about Zoetis’s arthritis drugs, Librela (for dog) and Solensia (for cats), due to negative side effects. Additionally, the article reported that U.S. and Europe health regulators are conducting reviews of the drugs.
Following this news, Zoetis’s stock price fell 8%, to close at $149.98 per share on April 12, 2024.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.